These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 852497)

  • 21. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
    Cohen D; Bogers JP; van Dijk D; Bakker B; Schulte PF
    J Clin Psychiatry; 2012 Oct; 73(10):1307-12. PubMed ID: 23140648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hematologic effects of clozapine: a review of the international experience].
    Lamarque V
    Encephale; 1996 Dec; 22 Spec No 6():35-6. PubMed ID: 9102319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.
    Honigfeld G
    Psychiatr Serv; 1996 Jan; 47(1):52-6. PubMed ID: 8925346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notes from a state mental health directors' meeting on clozapine.
    Salzman C
    Hosp Community Psychiatry; 1990 Aug; 41(8):838-9, 842. PubMed ID: 2401474
    [No Abstract]   [Full Text] [Related]  

  • 25. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies.
    Li XH; Zhong XM; Lu L; Zheng W; Wang SB; Rao WW; Wang S; Ng CH; Ungvari GS; Wang G; Xiang YT
    Psychol Med; 2020 Mar; 50(4):583-594. PubMed ID: 30857568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tardive dyskinesia.
    Elmes P
    Br Med J; 1980 Jan; 280(6209):255. PubMed ID: 7427106
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hematologic effects of clozapine: evaluation of the international experience].
    Lamarque V
    Encephale; 1995 Jun; 21 Spec No 3():59-60. PubMed ID: 7628344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
    Schulte P
    Ann Pharmacother; 2006 Apr; 40(4):683-8. PubMed ID: 16595571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of the Clozaril Patient Management System.
    Bastani B; Alphs LD; Meltzer HY
    Psychopharmacology (Berl); 1989; 99 Suppl():S122-5. PubMed ID: 2813664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA's position on the clozaril patient management system.
    Peck CC
    Hosp Community Psychiatry; 1990 Aug; 41(8):876-7. PubMed ID: 2401475
    [No Abstract]   [Full Text] [Related]  

  • 31. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.
    Honigfeld G; Arellano F; Sethi J; Bianchini A; Schein J
    J Clin Psychiatry; 1998; 59 Suppl 3():3-7. PubMed ID: 9541331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine treatment after agranulocytosis induced by classic neuroleptics.
    Bauer M; Mackert A
    J Clin Psychopharmacol; 1994 Feb; 14(1):71-3. PubMed ID: 7908676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012).
    Balda MV; Garay OU; Papale RM; Bignone I; Bologna VG; Brandolini A; Prokopez CR; Balasini JI; Baldessarini RJ; Daray FM
    Int Clin Psychopharmacol; 2015 Mar; 30(2):109-14. PubMed ID: 25486383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematological adverse events in clozapine-treated children and adolescents.
    Gerbino-Rosen G; Roofeh D; Tompkins DA; Feryo D; Nusser L; Kranzler H; Napolitano B; Frederickson A; Henderson I; Rhinewine J; Kumra S
    J Am Acad Child Adolesc Psychiatry; 2005 Oct; 44(10):1024-31. PubMed ID: 16175107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors.
    Lieberman JA; Alvir JM
    Drug Saf; 1992; 7 Suppl 1():1-2. PubMed ID: 1503671
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of clozapine monitoring after the first 6 months.
    Zhang M; Owen RR; Pope SK; Smith GR
    Arch Gen Psychiatry; 1996 Oct; 53(10):954-8. PubMed ID: 8857873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late-onset clozapine-induced agranulocytosis in a patient with comorbid multiple sclerosis.
    Raveendranathan D; Sharma E; Venkatasubramanian G; Rao MG; Varambally S; Gangadhar BN
    Gen Hosp Psychiatry; 2013; 35(5):574.e5-6. PubMed ID: 22902258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sudden late onset of clozapine-induced agranulocytosis.
    Patel NC; Dorson PG; Bettinger TL
    Ann Pharmacother; 2002 Jun; 36(6):1012-5. PubMed ID: 12022904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
    Alvir JM; Lieberman JA; Safferman AZ; Schwimmer JL; Schaaf JA
    N Engl J Med; 1993 Jul; 329(3):162-7. PubMed ID: 8515788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic factors in clozapine-induced agranulocytosis.
    Reznik I; Mester R
    Isr Med Assoc J; 2000 Nov; 2(11):857-8. PubMed ID: 11344758
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.